Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leucine phosphonic acid is a synthetic analog of the amino acid leucine, in which the carboxylic acid group is replaced by a phosphonic acid moiety. It is classified as an organic phosphonic acid and has the molecular formula C5H14NO3P with a molecular weight of approximately 167.14. Leucine phosphonic acid acts as a bioactive small molecule and has been studied primarily as an experimental compound, not approved for clinical use. Its primary research interest lies in its role as an inhibitor of aminopeptidases, particularly leucine aminopeptidase and alanyl aminopeptidase (APN). Studies have shown that it can inhibit these enzymes at low micromolar concentrations, making it useful for probing enzyme function or potentially modulating processes such as angiogenesis and tumorigenesis in preclinical models[5]. However, there are no approved indications or clinical trials involving this compound to date[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leucine phosphonic acid.